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Objectives We investigated coronary atheroma progression in patients with low levels of low-density lipoprotein cholesterol
(LDL-C) and systolic blood pressure (SBP).
Background Low LDL-C and SBP beneficially impact coronary atherosclerosis. However, the association between intensive
control of both risk factors and coronary plaque progression remains unclear.
Methods Changes in atheroma burden monitored by intravascular ultrasound were studied in 3,437 patients with coro-
nary artery disease (CAD) who were stratified according to on-treatment LDL-C and SBP.
Results Patients with very low LDL-C (70 mg/dl) and normal SBP (120 mm Hg) had less progression in percent ath-
eroma volume (PAV) (p  0.001) and total atheroma volume (TAV) (p  0.001), more frequent plaque regres-
sion (p  0.01), and less frequent plaque progression (p  0.001). In patients with SBP 120 mm Hg, very low
LDL-C was associated with less progression of PAV (0.30%, 95% confidence interval [CI]: 0.17% to 0.77% vs.
0.61%, 95% CI: 0.17% to 1.05%, p  0.01) and TAV (3.9 mm3, 95% CI: 7.24 to 0.63 mm3 vs. 1.2 mm3,
95% CI: 4.31 to 1.92 mm3, p  0.001). In patients with LDL-C 70 mg/dl, normal SBP was not associated with
less progression of PAV (0.51%, 95% CI: 0.04% to 0.99% vs. 0.61%, 95% CI: 0.17% to 1.05%, p  0.159) or TAV
(2.3 mm3, 95% CI: 5.59 to 1.05 mm3 vs. 1.2 mm3, 95% CI: 4.31 to 1.92 mm3, p  0.617).
Conclusions Very low LDL-C and normal SBP are associated with the slowest progression of coronary atherosclerosis. Al-
though a greater beneficial association is observed in patients with very low LDL-C, these findings suggest the
need for intensive control of global risk in patients with CAD. (J Am Coll Cardiol 2009;53:1110–5) © 2009 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.065e
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Tow density lipoprotein cholesterol (LDL-C) plays a piv-
tal role in the progression of atherosclerotic coronary artery
isease (CAD). Clinical trials have demonstrated that low-
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ccepted September 22, 2008.ring LDL-C with statins prevents cardiovascular events
1,2) and that intensive LDL-C lowering is associated with
dditional benefit in terms of clinical events and plaque
rogression (3,4). Accordingly, the National Cholesterol
ducation Program (NCEP) guidelines now include an
DL-C goal 100 mg/dl for patients with CAD and an
ptional goal 70 mg/dl for very high-risk patients (5).
See page 1116
Similarly, blood pressure (BP) plays an important role in
he promotion of CAD. In epidemiological studies, cardio-
ascular event rates increase with BP 115/75 mm Hg (6).
iven that relatively mild increases in BP can increase
ardiovascular risk, the Seventh Report of the Joint National
ommittee on Prevention, Detection, Evaluation, and
reatment of High Blood Pressure (JNC-7) defines “pre-
ypertension” as a BP of 120 to 139/80 to 89 mm Hg (7)
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March 31, 2009:1110–5 Effects of LDL and SBP on Coronary Atherosclerosisnd recommends consideration of pharmacological therapy for
re-hypertensive patients with compelling indications, includ-
ng chronic kidney disease or diabetes. Interestingly, estab-
ished CAD is not regarded as a compelling indication for drug
herapy in pre-hypertensive patients. The observation that
ormotensive patients have less coronary plaque progression
han hypertensive and pre-hypertensive patients (8) suggests
hat more intensive BP lowering than currently recommended
ay be beneficial.
Animal studies have indicated that BP and cholesterol-
owering therapy in combination may slow the progression
f aortic atherosclerosis (9,10). However, the impact of
imultaneous optimal control of LDL-C and BP in humans
as not been defined. The current study characterizes the
elationship between low levels of both LDL-C and systolic
lood pressure (SBP) and coronary plaque progression.
ethods
atients with established CAD who underwent serial intra-
ascular ultrasound (IVUS) examination in 7 clinical trials
ere included for analysis (Table 1) (4,11–16). Each study
as approved by the institutional review boards of the
articipating clinical trial sites, and all participants in the
rials provided informed written consent before enrollment.
ollow-up IVUS examination was performed between 18
nd 24 months.
The methods for acquisition and analysis of IVUS images
ave been described previously (4,11–16). Lumen and
xternal elastic membrane volumes, normalized total ather-
ma volume (TAV), and percent atheroma volume (PAV)
n the target segment were calculated in each patient at
aseline and at follow-up. Substantial plaque progression
rug Regimens Used in Each Constituent Trial
Table 1 Drug Regimens Used in Each Constituent Trial
Trial n Study Group(s)
REVERSAL (11) 502 1. Atorvastatin
2. Pravastatin
CAMELOT (12) 249 1. Enalapril
2. Amlodipine
3. Placebo
ACTIVATE (13) 408 1. Pactimibe
2. Placebo
ASTEROID (4) 349 Rosuvastatin
ILLUSTRATE (14) 897 1. Atorvastatin  torcetrapib
2. Atorvastatin  placebo
PERISCOPE (15) 360 1. Pioglitazone
2. Glimepiride
STRADIVARIUS (16) 672 1. Rimonabant
2. Placebo
CTIVATE  ACAT Intravascular Atherosclerosis Treatment Evaluation; ASTEROID  A Study to
valuate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma
urden; CAMELOT  Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis;
LLUSTRATE  Investigation of Lipid Level Management Using Coronary Ultrasound To Assess
eduction of Atherosclerosis by CETP Inhibition and HDL Elevation; PERISCOPE  Pioglitazone
ffect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation;
EVERSAL Reversing Atherosclerosis with Aggressive Lipid Lowering; STRADIVARIUS Strategyn
o Reduce Atherosclerosis Development InVolving Administration of Rimonabant–the Intravascu-
ar Ultrasound Study.nd regression were pre-specified
s a 5% relative increase or de-
rease in PAV.
tatistical analysis. Continuous
ariables are expressed as mean
SD and categorical variables as
ercentage. Patients were strati-
ed into 4 subgroups based on
verage on-treatment SBP  or
120 mm Hg and average on-
reatment LDL-C level or70
g/dl. Groups were compared
ith respect to clinical characteris-
ics, medication use, and athero-
clerotic plaque burden at baseline
nd during follow-up with use of
he chi-square statistic. Compari-
ons between least squared mean
SEM changes in PAV and
AV were performed with the use
f a random effects mixed model
ith baseline plaque burden as a
ovariate and with trial as a ran-
om factor to control for any het-
rogeneity across the 7 studies. A
est for trend across the 4 groups
lso was performed. Potential confounding factors such as
aseline atheroma burden, age, diabetes, previous myocardial
nfarction, baseline LDL-C, and baseline SBP were controlled.
tatistical analyses were performed with SAS version 8.2 (SAS
nstitute, Cary, North Carolina). A value of p  0.05 was
onsidered significant.
esults
atient characteristics. Clinical characteristics and base-
ine atheroma burden are summarized in Table 2. Patients
ere predominantly male (70.6%) with a high prevalence of
ypertension (79.2%), hyperlipidemia (75.4%), and diabetes
31.3%). Aspirin use was similar across groups at baseline;
owever, there were differences in statin, beta-blocker,
ngiotensin-converting enzyme inhibitor, and calcium-
hannel blocker use across groups. Baseline atheroma vol-
me was greatest in patients with poor risk factor control.
egree of risk factor control with treatment. Clinical
haracteristics during follow-up are summarized in Table 3.
ean LDL-C in groups III and IV was 100 mg/dl, in
ccordance with current NCEP guidelines. In contrast,
ean LDL-C in groups I and II was significantly lower,
pproaching 55 mg/dl. Mean blood pressures in groups II
nd IV were 135/77 and 134/78 mg/dl, respectively, falling
nto the “pre-hypertension” category of the JNC-7 guide-
ines. However, mean blood pressures in groups I and III
ere 113/70 and 114/71 mg/dl, respectively, within the
Abbreviations
and Acronyms
BP  blood pressure
CAD  coronary artery
disease
CI  confidence interval
IVUS  intravascular
ultrasound
JNC-7  Seventh Report of
the Joint National
Committee on Prevention,
Detection, Evaluation, and
Treatment of High Blood
Pressure
LDL-C  low-density
lipoprotein cholesterol
NCEP  National
Cholesterol Education
Panel
PAV  percent atheroma
volume
SBP  systolic blood
pressure
TAV  total atheroma
volumeormal range.
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Effects of LDL and SBP on Coronary Atherosclerosis March 31, 2009:1110–5ffect on atheroma progression. Serial changes in ather-
ma burden are illustrated in Figure 1. Lower levels of
DL-C and SBP were associated with less progression of
AV and TAV (p  0.001 for trend), less frequent
ubstantial atheroma progression (p  0.001 for trend), and
ore frequent substantial atheroma regression (p 0.01 for
aseline Clinical Characteristics
Table 2 Baseline Clinical Characteristics
Group I (n  263) Gro
SBP <120 mm Hg SB
LDL-C <70 mg/dl LD
Age (yrs) 56  9
Caucasian 94.7%
Male sex 75.3%
Hyperlipidemia 65.4%
Hypertension 74.9%
Previous percutaneous coronary
intervention
48.5%
Previous myocardial infarction 38.4%
Previous coronary bypass surgery 2.0%
Diabetes mellitus 27.4%
Current tobacco use 21.1%
Statin use 75.3%
Beta-blocker use 81.4%
ACE inhibitor use 55.9%
Calcium-channel blocker use 35.0%
Aspirin use 95.8%
Systolic BP (mm Hg) 116  13
Diastolic BP (mm Hg) 71  9
LDL-C (mg/dl) 88  35
High-density lipoprotein cholesterol (mg/dl) 42  11
Baseline TAV (mm3) 183.0  82.2 1
Baseline PAV (mm3) 37.5  8.6
From REVERSAL 9.5%
From CAMELOT 1.5%
From ACTIVATE 8.0%
From ASTEROID 22.4%
From ILLUSTRATE 38.0%
From PERISCOPE 7.2%
From STRADIVARIUS 13.3%
CE  angiotensin-converting enzyme; BP  blood pressure; LDL-C  low-density lipoprotein chol
ther abbreviations as in Table 1.
n-Treatment Clinical Characteristics
Table 3 On-Treatment Clinical Characteristics
Group I
SBP <120 mm Hg SBP
LDL-C <70 mg/dl LD
Systolic BP (mm Hg) 113  6
Diastolic BP (mm Hg) 70  7
LDL-C (mg/dl) 57  9
High-density lipoprotein cholesterol (mg/dl) 51  18
Statin use 98.9%
Beta-blocker use 81.7%
ACE inhibitor use 61.2%
Calcium-channel blocker use 33.5%
Aspirin use 95.8%bbreviations as in Table 2.rend). In patients with SBP 120 mm Hg, very low
DL-C (70 mg/dl) was associated with less progression
n PAV (0.30%, 95% confidence interval [CI]: –0.17% to
.77% vs. 0.61%, 95% CI: 0.17% to 1.05%, p  0.01) and
AV (–3.9 mm3, 95% CI: –7.24 to –0.63 mm3 vs. –1.2 mm3,
5% CI: –4.31 to 1.92 mm3, p  0.001). In patients with
n  688) Group III (n  622) Group IV (n  1,864)
p Value
0 mm Hg SBP <120 mm Hg SBP >120 mm Hg
70 mg/dl LDL-C >70 mg/dl LDL-C >70 mg/dl
9 54  9 58  9 0.01
.6% 92.3% 90.9% 0.04
.8% 71.9% 69.2% 0.13
.2% 75.7% 79.7% 0.01
.8% 62.4% 83.0% 0.01
.4% 42.8% 44.2% 0.57
.2% 37.0% 27.4% 0.01
.9% 2.7% 3.2% 0.50
.5% 23.8% 34.3% 0.01
.4% 26.8% 21.8% 0.01
.7% 81.8% 76.5% 0.01
.6% 73.5% 73.0% 0.02
.4% 44.4% 50.1% 0.01
.8% 24.1% 34.0% 0.01
.9% 94.4% 92.4% 0.09
16 117  13 131  16 0.01
9 72  8 77  9 0.01
37 105  35 109  36 0.01
12 43  12 43  12 0.35
76.6 182.4  82.1 195.7  85.4 0.01
9.1 37.3  9.1 39.1  9.1 0.01
.3% 12.5% 15.8% 0.01
.3% 11.9% 8.3% 0.01
.2% 10.4% 15.0% 0.01
.4% 6.1% 5.3% 0.01
.6% 34.1% 20.8% 0.01
.0% 9.3% 12.6% 0.01
.2% 15.6% 22.3% 0.01
PAV  percent atheroma volume; SBP  systolic blood pressure; TAV  total atheroma volume;
p II Group III Group IV
p Value
0 mm Hg SBP <120 mm Hg SBP >120 mm Hg
0 mg/dl LDL-C >70 mg/dl LDL-C >70 mg/dl
11 114  5 134  11 0.01
7 71  5 78  7 0.01
10 95  19 99  23 0.01
18 47  14 47  15 0.01
7% 94.5% 93.0% 0.01
1% 75.6% 75.3% 0.08
6% 51.1% 56.1% 0.02
0% 26.7% 41.1% 0.01
9% 95.2% 93.9% 0.42up II (
P >12
L-C <
61 
93
71
67
85
44
27
3
31
15
67
75
48
36
93
131 
76 
92 
42 
89.3 
38.6 
15
2
6
22
28
7
18Grou
>12
L-C <7
135 
77 
57 
50 
97.
78.
53.
43.
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March 31, 2009:1110–5 Effects of LDL and SBP on Coronary Atherosclerosisormal SBP (120 mm Hg), very low LDL-C was associated
ith less progression in PAV (0.15%, 95% CI: –0.38% to
.67% vs. 0.51%, 95% CI: 0.04% to 0.99%, p 0.05), and no
ignificant reduction in TAV (–2.3 mm3, 95% CI: –5.6 to 1.05
m3 vs. –4.2 mm3, 95% CI: –7.83 to –0.49 mm3, p 0.141).
n the setting of LDL-C 70 mg/dl, normal SBP was
ssociated with no greater reduction in PAV (0.51%, 95%
I: 0.04% to 0.99% vs. 0.61%, 95% CI: 0.17% to 1.05%, p
0.159) or in TAV (–1.2 mm3, 95% CI: –4.31 to 1.92 mm3
Figure 1 Serial Changes in Atheroma Burden
Change in percent atheroma volume (PAV) and total atheroma volume (TAV) and p
progression and regression, stratified according to on-treatment low-density lipopro
Figure 2 Serial Changes in Vessel Wall Volumes
Change in lumen and external elastic membrane (EEM) volumes, stratified accordis. –2.3 mm3, 95% CI: –5.59 to 1.05 mm3, p  0.617),
uggesting that lower levels of LDL-C had a greater impact on
rogression of CAD than SBP.
Serial changes in lumen and external elastic membrane
olumes are illustrated in Figure 2. No change in lumen
olume was observed, whereas lower levels of LDL-C and
BP were associated with a reduction in external elastic
embrane volume (p  0.03 for trend), suggestive of
egative remodeling.
age of subjects undergoing substantial atheroma
holesterol (LDL-C) and systolic blood pressure (SBP).
n-treatment LDL-C and SBP. Abbreviations as in Figure 1.ercent
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ncreasing evidence suggests that intensive risk factor man-
gement beyond that currently proposed by guidelines has a
eneficial impact in patients at risk for cardiovascular events.
he current analysis demonstrated the slowest CAD pro-
ression in subjects with the lowest levels of both LDL-C
nd SBP. These results suggest the need to achieve optimal
anagement of global risk in patients with established
AD.
Early studies demonstrated that lowering LDL-C slows
he rate of progression of CAD on serial coronary angiog-
aphy (17). Precise quantification of atheroma volume using
VUS has demonstrated that intensive lowering of LDL-C
an halt progression of CAD (11) or even promote athero-
clerotic regression (4). These observations complement
tudies demonstrating a reduction in cardiovascular events
ith LDL-C–lowering therapy and suggest a potential
echanism underlying this benefit. However, despite the
ompelling evidence regarding the benefits of lowering
DL-C, the optimal LDL-C goal for high-risk patients
emains unclear.
Hypertension is highly prevalent in patients with CAD,
nd increasing evidence has challenged the concept that BP
eed only be treated when 140/90 mm Hg. Clinical
vents and plaque progression are reduced when BP is
ithin the normal range. Pre-hypertension confers a 2-fold
ncrease in event rates compared with normal BP (18),
mphasizing the heightened cardiovascular risk in patients
ith even mild BP elevations. Despite these observations,
he JNC-7 guidelines do not recommend initiation of BP
owering agents in pre-hypertensive patients with CAD.
Despite the evidence demonstrating the cardiovascular
enefits of LDL-C and BP lowering, patients are subopti-
ally treated. Antihypertensive medication is prescribed in
nly 25% to 50% of cases of hypertension in North America
nd Europe (19), and global rates of hypertension control to
140/90 mm Hg range from only 5.4% in Korea to 58% in
arbados (20). The management of LDL-C remains sub-
ptimal even in patients at high cardiovascular risk, with
nly 40% to 50% of patients achieving LDL-C targets in
he U.S. (21) and Europe (22).
Interestingly, the current findings suggest that very low
DL-C levels are associated with less atheroma progression
han normal SBP, supporting the evidence that intensively
owering LDL-C has a beneficial impact on plaque progres-
ion and clinical events in randomized controlled trials. In
act, LDL-C may be a stronger promoter of plaque pro-
ression than elevated SBP. Accordingly, very low LDL-C
ay have a more rapid or profound impact than normal
BP on attenuation of atheroma progression by slowing
ccumulation of lipid in the arterial wall.
The incremental effect of low SBP is less well understood.
lthough normal SBP alone was not associated with atten-
ated atheroma progression, fewer patients with normal
BP and very low LDL-C in combination (group I) oemonstrated substantial plaque progression. Importantly,
ean SBP in groups II and IV and LDL-C in groups III
nd IV was in accordance with the current JNC-7 and
CEP guidelines. However, patients in group I demon-
trated the greatest attenuation in coronary plaque progres-
ion. This trend was observed in all IVUS measurements
valuated in this study. Furthermore, correction for baseline
BP and LDL-C in our model had no impact on these
ndings. These data support the notion that global risk
actor modification can slow the progression of CAD even
hen these risk factors are near the normal range.
Alternatively, the stronger association between very low
DL-C and attenuated atheroma progression may reflect
he constituent clinical trials in the pooled analysis. The
nclusion of 5 studies of lipid lowering and only 1 trial of
lood pressure lowering in a small cohort may have con-
ributed to the findings. The relative difference in LDL-C
etween groups was approximately 40%, with the difference
n SBP only 15%. Therefore, a large clinical trial of antihy-
ertensive therapy in patients with CAD may better define the
mpact of low levels of SBP on plaque progression.
This study is the first to demonstrate that normal BP and
ery low LDL-C in combination is associated with atten-
ated progression of CAD in humans. A small study
eported that simvastatin, but not enalapril, had a beneficial
ffect on CAD in humans; however, the degree of BP and
DL-C control in that study were not optimal by current
tandards (23). Furthermore, the previous study assessed
laque progression by the use of coronary angiography
ather than IVUS and, therefore, did not evaluate the
mpact of therapy on the full extent of disease.
The authors of SANDS (Stop Atherosclerosis in Native
iabetics Study) recently evaluated an aggressive strategy of
P and cholesterol management, reporting improvements
n carotid intimal medial thickness and cross-sectional area
ith aggressive risk factor management (24); however, post
oc analysis suggested that this improvement was more
losely correlated with cholesterol lowering than BP lower-
ng. Our findings are complementary, suggesting that very
ow LDL-C and normal SBP impact coronary as well as
arotid atherosclerosis, and that the impact of very low
DL-C may be greater than that of normal SBP.
Although these data reflect the relationship among
DL-C, SBP, and coronary atheroma progression, the
esultant impact on clinical events remains to be deter-
ined. This analysis represents an observational study that
sed pooled data from clinical trials and makes no inferences
bout the use of specific strategies to lower BP or LDL-C.
urthermore, the number of patients achieving very low
DL-C and normal SBP in combination was relatively
mall and some of the group-to-group comparisons failed to
each statistical significance. Therefore, these findings
hould be more rigorously tested in the setting of a random-
zed clinical trial. The effects of risk factors outside of SBP
nd LDL-C, including glycemic control, tobacco use, and
besity, were not evaluated in this study. Patients who
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March 31, 2009:1110–5 Effects of LDL and SBP on Coronary Atherosclerosischieved normal SBP and very low LDL-C in this study
ay have been more compliant with medical therapy or
ith healthy lifestyle modifications. Nevertheless, the re-
ults of this analysis suggest that a global risk factor
odification strategy may optimize outcomes in patients
ith established CAD.
In this study, the greatest attenuation of coronary plaque
rogression was observed in patients with very low LDL-C
nd normal SBP in combination. Importantly, these data
emonstrate that intensive BP and cholesterol control are
ssociated with attenuation of plaque progression even when
hese values are near the normal range. These findings
rovide important mechanistic information about the effects
f LDL-C and SBP on cardiovascular disease and support
he need for intensive management of global risk in patients
ith CAD. A randomized controlled trial to directly test
he clinical benefit obtained via intensive management of
ultiple risk factors would provide further support for this
oncept.
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